Rifaximin
Cat.No:IR0880 Solarbio
CAS:80621-81-4
Molecular Formula:C43H51N3O11
Molecular Weight:785.88
Storage:Powder:2-8℃,2 years;Insolvent(Mother Liquid):-20℃,6 months;-80℃,1 year
Purity:≥98%
Appearance:Orange to red Solid
Qty:
Size:
{{cart_num}}
My CartCAS:80621-81-4
Molecular Formula:C43H51N3O11
Molecular Weight:785.88
Storage:Powder:2-8℃,2 years;Insolvent(Mother Liquid):-20℃,6 months;-80℃,1 year
Purity:≥98%
Appearance:Orange to red Solid
Qty:
Size:
CAS | 80621-81-4 |
Name | Rifaximin |
Molecular Formula | C43H51N3O11 |
Molecular Weight | 785.88 |
Solubility | Soluble in DMSO ≥25mg/mL |
Purity | ≥98% |
Appearance | Orange to red Solid |
Storage | Powder:2-8℃,2 years;Insolvent(Mother Liquid):-20℃,6 months;-80℃,1 year |
EC | EINECS 617-130-4 |
MDL | MFCD00864973 |
SMILES | O=C1C2=C(O[C@@]1(O/C=C/[C@@H]([C@H]([C@H]([C@@H]([C@@H]([C@@H]([C@@H](O)[C@@H](C)/C=C/C=C(C)\C3=O)C)O)C)OC(C)=O)C)OC)C)C(C)=C(O)C4=C2C5=C(C(N3)=C4O)N6C(C=C(C)C=C6)=N5 |
Target Point | Bacterial |
Passage | Anti-infection |
Background | Rifaximin is a selective antibiotic that binds to the beta subunit of bacterial DNA-dependent RNA polymerase, thereby inhibiting bacterial RNA synthesis. |
Biological Activity | Rifaximin是一种RNA合成抑制剂,结合细菌DNA依赖RNA聚合酶的β亚基。Rifaximin是human nuclear receptor pregnane-X receptor(PXR)的肠道特异性配体,有助于维持肠道免疫稳态。Rifaximin可消除脂多糖引起的NF-κB结合[1]。 |
Data Literature Source | [1]Eur J Pharmacol. 2011 Oct 1;668(1-2):317-24; J Pharmacol Exp Ther. 2007 Jul;322(1):391-8. |
Unit | Bottle |
Specification | 200mg 500mg 1g |
Remark:These protocols are for reference only. Solarbio does not independently validate these methods.
Note:
1. The products are all for scientific research use only. Do not use it for medical, clinical diagnosis or treatment, food and cosmetics, etc. Do not store them in ordinary residential areas.
2. For your safety and health, please wear laboratory clothes, disposable gloves and masks.
3. The experimental results may be affected by many factors, after-sale service is limited to the product itself and does not involve other compensation.
Sorry, there is no more information.
Sorry, there is no more information.